Abstract:CDK2, which interacts with cyclin A and cyclin E, is an important member of the CDK family. Having been proved to be associated with many diseases for its vital role in cell cycle, CDK2 is a promising target of anti-cancer drugs dealing with cell cycle disorders. In the present work, a total of 111 pyrazolo[1,5-a]pyrimidines (PHTPPs) as CDK2/cyclin A inhibitors were studied to conduct three-dimensional quantitative structure-activity (3D-QSAR) analyses. The optimal comparative molecular similarity indices analysis (CoMSIA) model shows that Q(2) = 0.516, R-ncv(2) = 0.912, R-pre(2) = 0.914, R-m(2) = 0.843, SEP = 0.812, SEE = 0.347 with 10 components using steric, hydrophobic and H-bond donor field descriptors, indicating its effective internal and external predictive capacity. The contour maps further indicate that (1) bulky substituents in R-1 are beneficial while H-bond donor groups at this position are detrimental; (2) hydrophobic contributions in the R-2 area are favorable; (3) large and hydrophilic groups are well tolerated at the R-3 position (a close H-bond donor moiety is favorable while a distal H-bond donor moiety in this area is disfavored); (4) bulky and hydrophobic features in the R-4 region are beneficial for the biological activities and (5) the 7-N-aryl substitution is crucial to boost the inhibitory activities of the PHTPP inhibitors. Finally, docking and MD simulations demostrate that PHTPP derivatives are stabilized in a 'flying bat' conformation mainly through the H-bond interactions and hydrophobic contacts. Comparative studies indicate that PHTPP derivatives fit well within the ATP binding cleft in CDK2, with the core heterocyclic ring overlapping significantly with the adenine group of ATP despite a small deflection. In comparison to numerous other inhibitors binding to the ATP pocket, PHTPP analogues follow the binding fashion of purine inhibitors of this kinase. It is anticipated that the binding mechanism and structural features of PHTPP inhibitors studied in the present work will benefit the discovery of more potent CDK2 inhibitors, and the valid pyrazolo[1,5-a]pyrimidine-7-N-yl inhibitors will soon emerge from the large number of screening programmes to enter in clinical studies.

D-QSAR studies on pyrimidine analogues as cyclin-dependent kinase 1 inhibitors

3D-QSAR Study for Inhibitors of Cyclin-Dependent Kinase 4

3D-QSAR and Docking Studies on Pyrazolo[4,3-H]qinazoline-3-carboxamides As Cyclin-Dependent Kinase 2 (CDK2) Inhibitors.

Molecular-docking-guided 3D-QSAR Studies of Substituted Isoquinoline-1,3-(2h,4h)-diones As Cyclin-Dependent Kinase 4 (CDK4) Inhibitors.

Development of in Silico Models for Pyrazoles and Pyrimidine Derivatives As Cyclin-Dependent Kinase 2 Inhibitors

3D-QSAR and 3D-QSSR Studies of Thieno[2,3-D]pyrimidin-4-yl Hydrazone Analogues As CDK4 Inhibitors by CoMFA Analysis

3D-QSAR and Molecular Docking Study on Selectivity of Indolocarbazole Series As Cyclin-Dependent Kinase Inhibitors

An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.

Using 3D-QSAR and Molecular Docking Insight into Inhibitors Binding with Complex-Associated Kinases CDK8

Three-dimensional Quantitative Structure-Activity Relationships of Pyrrolopyridinone As Cell Division Cycle Kinase Inhibitors by CoMFA and CoMSIA.

Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.

Insight into the Interactions Between Novel Isoquinolin-1,3-dione Derivatives and Cyclin-Dependent Kinase 4 Combining QSAR and Molecular Docking.

Molecular Docking, QSAR and Molecular Dynamics Simulation on Phosphorus Containing Pyrimidines As CDK9 Inhibitors

Molecular Docking and 3D-QSAR Studies on Checkpoint Kinase 1 Inhibitors

Pyrrolo[3,2-d]pyrimidine Derivatives As Type II Kinase Insert Domain Receptor (KDR) Inhibitors: CoMFA and CoMSIA Studies

Discovery of 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine as Novel Cyclin-dependent Kinases 4 and 6 Dual Inhibitors via 3<i>D</i>-QSAR and Molecular Simulation

Combined Pharmacophore Modeling, Docking, And 3d-Qsar Studies Of Plk1 Inhibitors

3D-QSAR Study on 2,3-Dihydroimidazo[4,5]-pyridin-2-one Derivatives with a Meta Substitution Pattern As V600E BRAF Inhibitors

Homology Modeling, Molecular Docking, And 3d-Qsar Of Indirubin Analogues As Cdk1 Inhibitors

Molecular docking-based 3D-QSAR studies of pyrrolo[3,4-c]pyrazole derivatives as Aurora-A inhibitors

Synthesis, Biological Evaluation and Molecular Docking Studies of Pyrazole Derivatives Coupling with a Thiourea Moiety As Novel CDKs Inhibitors.